131 related articles for article (PubMed ID: 21852619)
1. Blood pressure management in acute stroke: does the Scandinavian Candesartan Acute Stroke Trial (SCAST) resolve all of the unanswered questions?
Fischer U; Rothwell PM
Stroke; 2011 Oct; 42(10):2995-8. PubMed ID: 21852619
[No Abstract] [Full Text] [Related]
2. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
Sandset EC; Bath PM; Boysen G; Jatuzis D; Kõrv J; Lüders S; Murray GD; Richter PS; Roine RO; Terént A; Thijs V; Berge E;
Lancet; 2011 Feb; 377(9767):741-50. PubMed ID: 21316752
[TBL] [Abstract][Full Text] [Related]
3. Lowering blood pressure in acute stroke: the SCAST trial.
Hankey GJ
Lancet; 2011 Feb; 377(9767):696-8. PubMed ID: 21316753
[No Abstract] [Full Text] [Related]
4. Relation between change in blood pressure in acute stroke and risk of early adverse events and poor outcome.
Sandset EC; Murray GD; Bath PM; Kjeldsen SE; Berge E;
Stroke; 2012 Aug; 43(8):2108-14. PubMed ID: 22627991
[TBL] [Abstract][Full Text] [Related]
5. Renin-angiotensin system blockade safely reduces blood pressure in patients with minor ischemic stroke during the acute phase.
Nakamura T; Tsutsumi Y; Shimizu Y; Uchiyama S
J Stroke Cerebrovasc Dis; 2010; 19(6):435-40. PubMed ID: 20702114
[TBL] [Abstract][Full Text] [Related]
6. Noncholestatic acute hepatocellular injury following candesartan administration.
Lammel-Lindemann JA; Flores-Villalba E; Martagón AJ; DeObeso-Gonzalez E; Puente-Gallegos F
Br J Clin Pharmacol; 2018 Jan; 84(1):204-207. PubMed ID: 28841231
[TBL] [Abstract][Full Text] [Related]
7. Effects of candesartan in acute stroke on cognitive function and quality of life: results from the Scandinavian Candesartan Acute Stroke Trial.
Hornslien AG; Sandset EC; Bath PM; Wyller TB; Berge E;
Stroke; 2013 Jul; 44(7):2022-4. PubMed ID: 23660849
[TBL] [Abstract][Full Text] [Related]
8. A Randomized, Double-blind, Candesartan-controlled, Parallel Group Comparison Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Patients with Mild to Moderate Essential Hypertension.
Lee JH; Yang DH; Hwang JY; Hur SH; Cha TJ; Kim KS; Kim MH; Chun KJ; Cha GS; Hong GR; Lee SG; Kim DS; Kim DI; Chae SC
Clin Ther; 2016 Jun; 38(6):1485-1497. PubMed ID: 27161546
[TBL] [Abstract][Full Text] [Related]
9. Effects of Candesartan in the Acute Phase of Intracerebral Hemorrhage.
Jusufovic M; Berge TE; Guo R; You S; Delcourt C; Anderson C; Bath PM; Karlson BW; Berge E; Sandset EC;
J Stroke Cerebrovasc Dis; 2019 Aug; 28(8):2262-2267. PubMed ID: 31178359
[TBL] [Abstract][Full Text] [Related]
10. Increased renal echogenicity in a preterm neonate. Kidneys with tubular dysplasia due to exposure to candesartan during pregnancy.
Bald M; Holder M; Zieger M; Vochem M; Leichter HE
Pediatr Nephrol; 2005 Nov; 20(11):1664-5, 1666-8. PubMed ID: 16082550
[No Abstract] [Full Text] [Related]
11. Effects of candesartan in acute stroke on vascular events during long-term follow-up: results from the Scandinavian Candesartan Acute Stroke Trial (SCAST).
Hornslien AG; Sandset EC; Igland J; Terént A; Boysen G; Bath PM; Murray GD; Berge E
Int J Stroke; 2015 Aug; 10(6):830-5. PubMed ID: 25808741
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin receptor blockers and myocardial infarction.
Verma S; Strauss M
BMJ; 2004 Nov; 329(7477):1248-9. PubMed ID: 15564232
[No Abstract] [Full Text] [Related]
13. Rash and acute nephritic syndrome due to candesartan.
Morton A; Muir J; Lim D
BMJ; 2004 Jan; 328(7430):25. PubMed ID: 14703542
[No Abstract] [Full Text] [Related]
14. Stroke: blood pressure lowering in acute stroke--scant joy from SCAST.
Arima H; Chalmers J
Nat Rev Cardiol; 2011 Apr; 8(7):366-8. PubMed ID: 21587216
[No Abstract] [Full Text] [Related]
15. Concomitant administration of candesartan cilexetil in patients on paclitaxel and carboplatin combination therapy increases risk of severe neutropenia
.
Katsube Y; Hira D; Tsujimoto M; Koide H; Minegaki T; Ikeda Y; Morita SY; Nishiguchi K; Terada T
Int J Clin Pharmacol Ther; 2018 Jul; 56(7):328-336. PubMed ID: 29792394
[TBL] [Abstract][Full Text] [Related]
16. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex).
Ogihara T; Ueshima K; Nakao K; Fukiyama K; Oba K; Yasuno S; Fujimoto A; Sato T; Matsuoka H; Saruta T;
Hypertens Res; 2011 Dec; 34(12):1295-301. PubMed ID: 21833000
[TBL] [Abstract][Full Text] [Related]
17. Telmisartan and stroke reduction in the ONTARGET trial: benefit beyond blood pressure lowering?
Serebruany VL; Atar D; Hanley DF
Cerebrovasc Dis; 2008; 26(5):563-4. PubMed ID: 18936537
[No Abstract] [Full Text] [Related]
18. Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T).
Bönner G; Landers B; Bramlage P
Vasc Health Risk Manag; 2011; 7():85-95. PubMed ID: 21415922
[TBL] [Abstract][Full Text] [Related]
19. Safety of olmesartan in a patient with telmisartan-induced myotoxicity: a case report.
Barvaliya MJ; Naik VN; Shah AC; Tripathi CR
Br J Clin Pharmacol; 2015 Jun; 79(6):1034-6. PubMed ID: 25495498
[No Abstract] [Full Text] [Related]
20. The X-cellent Study.
Safar ME
Am J Hypertens; 2006 Jan; 19(1):8-9. PubMed ID: 16461182
[No Abstract] [Full Text] [Related]
[Next] [New Search]
